Wilson Wolf v. Nationwide Children’s Hospital: Cell Culture Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Wilson Wolf Manufacturing Corporation v. Nationwide Children’s Hospital Inc. |
| Case Number | 2:20-cv-00192 (S.D. Ohio) |
| Court | U.S. District Court for the Southern District of Ohio |
| Duration | Jan 2020 – Mar 2025 5 years 2 months |
| Outcome | Dismissed with prejudice – No Damages |
| Patents at Issue | |
| Accused Products | Corning HYPERStack® Cell Culture Device |
Case Overview
The Parties
⚖️ Plaintiff
Minnesota-based company known for developing gas-permeable cell culture technologies, including the G-Rex® platform.
🛡️ Defendant
Prominent academic medical institution with research in gene and cell therapy. Andelyn Biosciences, Inc. (CDMO spin-out) was successor-in-interest during litigation.
Patents at Issue
This case involved three U.S. patents covering cell culture vessel technology, specifically innovations related to gas-permeable material systems designed to optimize cell growth conditions:
- • US9441192B2 — Gas permeable cell culture device with multiple fluid and gas compartments
- • US8697443B2 — System and method for culturing cells in a gas-permeable vessel
- • US9732317B2 — Cell culture system with an optimized gas exchange surface
Developing cell culture technology?
Check if your bioprocessing design might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case concluded on **March 13, 2025**, via stipulated dismissal with prejudice pursuant to Fed. R. Civ. P. 41(a)(2) and 41(c). No damages were awarded, no injunction was entered, and each party agreed to bear its own costs. Critically, the dismissal included a **mutual release** extending to the parties, Andelyn Biosciences, Inc., and their respective customers.
Key Legal Issues
The resolution, involving a stipulated dismissal with prejudice and a mutual release, highlights the strategic importance of out-of-court settlements in complex patent disputes, particularly concerning foundational bioprocessing technologies. The inclusion of Andelyn Biosciences as successor-in-interest also demonstrates how corporate transformations can influence litigation outcomes and the scope of settlement, extending protection to downstream users.
Drafting patents for cell culture tech?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
🔬 Freedom to Operate (FTO) Analysis in Bioprocessing
This case highlights critical IP risks in cell culture technology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications for cell culture and bioprocessing.
- View related patents in scalable cell culture systems
- See which companies are most active in bioprocessing IP
- Understand claim scope for gas-permeable materials
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Gas-permeable cell culture vessel designs
3 Patents at Issue
In scalable cell culture technology
Dismissal with Release
Resolved out of court, protecting customers
✅ Key Takeaways
For Patent Attorneys & Litigators
Dismissal with prejudice and mutual releases (including customers) are powerful settlement tools in complex biotech cases.
Search related case law →Corporate succession (e.g., spin-outs like Andelyn) mid-litigation can significantly alter settlement dynamics and leverage.
Explore precedents →For IP Professionals & R&D Teams
Publicly available product documentation (protocols, videos) can serve as key evidence in infringement allegations—coordinate with IP counsel.
Start FTO analysis for my product →Conduct thorough FTO analysis for foundational bioprocessing technologies, especially gas-permeable cell culture systems, before deployment.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.